Impact of Trikafta on P2X7R and Clinical Outcomes in Cystic Fibrosis

The aim of this study is to assess the response of the ETI on P2X7R level as inflammatory marker and clinical outcomes in patients with cystic fibrosis.

Inclusion Criteria: * Confirmed diagnosis of Cystic Fibrosis according to CF Foundation guidelines (based on positive sweat chloride test and/or presence of disease-causing mutations in homozygous state or compound heterozygous state in CFTR gene). * Patients eligible for ETI therapy (having at least one F508del mutation or a mutation known to be responsive to ETI). * Age above 5 years old. Exclusion Criteria: * Known allergy or hypersensitivity to ETI or any of its components. * Moderate hepatic impairment (Child-Pugh Class B) or severe hepatic impairment (Child-Pugh Class C). * Presence of chronic inflammatory diseases unrelated to CF (e.g., Crohn's disease, glomerulonephritis, or thrombotic disorders) that could confound P2X7R levels.